Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study
vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony
Stimulating Factor (GM-CSF). Another purpose is to determine the type and severity of any
side effects associated with this study vaccine. GM-CSF is similar to a substance in the body
that stimulates the production of white blood cells. To create the study vaccine, cells will
be removed from the participants tumor and fused with dendritic cells which are obtained from
the participants blood. Dendritic cells are responsible for immune responses to "foreign"
substances that enter the body. Animal studies have shown that these fused cells can
stimulate powerful anti-tumor responses.